gPTX-L

gPTX-L is a liposomal formulation of glycosylated paclitaxel (gPTX, specifically 7-alpha-glucosyloxyacetylpaclitaxel). Developed by researchers at Okayama University and collaborating institutions, gPTX-L was designed to overcome the poor water solubility and pharmacokinetics of paclitaxel. By coupling glucose at the 7-OH position of paclitaxel, the resulting gPTX exhibits enhanced water solubility, allowing it to be efficiently encapsulated into liposomes using a remote loading method with a solubility gradient. gPTX-L acts as a tubulin stabilizer, inhibiting microtubule depolymerization and arresting cell division. It has been investigated in preclinical models for the treatment of various cancers, including breast cancer and ovarian cancer, often serving as a platform for active-targeting immunoliposomes (gPTX-IL) conjugated with antibodies such as trastuzumab or anti-CD44.

Other names

7-GLG-PT liposome7-alpha-glucosyloxyacetylpaclitaxel liposomegPTX liposomegPTX-encapsulated liposomeglycosylated paclitaxel liposome